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Abstract
Background: The quality of life (QoL) of patients with osteosarcoma (OS) may be adversely affected by the disease or its
treatment. Therefore, it is important to understand the QoL of patients undergoing treatment for OS to improve the QoL. We
report on the first prospective international QoL study that was embedded within a large randomized clinical trial from 4 national
study groups.
Objective: This paper aimed to describe the QoL study development, methodology, accrual details, and characteristics of the
QoL cohort.
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Methods: A total of 2260 patients registered in the EURopean AMerican Osteosarcoma Study-1 (EURAMOS-1), of whom
97.92% (2213/2260) were eligible for the optional QoL assessment and could participate in terms of questionnaire availability.
Overall, 61.86% (1369/2213) of patients and/or proxies completed the QoL evaluation at the first assessment time point (E1)
after the start of preoperative treatment. The QoL measures used (self- and/or proxy reports) depending on the patient’s age and
national study group. Participants and nonparticipants in the ancillary QoL study were compared regarding relevant demographic
and disease-related characteristics at registration in the trial.
Results: The participation rate at time point E1 did not differ with regard to age, gender, the occurrence of pathological fracture,
or the presence of any metastases at diagnosis. No differences were found regarding the primary tumor site. Only the national
study group affiliation had an influence on participation. Participation decreased linearly with trial progress up to 20% at the final
time point of QoL assessment.
Conclusions: This study demonstrates the feasibility of international cooperation for the purpose of assessing and understanding
the QoL of pediatric and adolescent/young adult patients with cancer. Future outcomes of this QoL substudy will help to adapt
interventions to improve QoL.
(JMIR Res Protoc 2019;8(8):e14406)  doi: 10.2196/14406
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Introduction
Treatment outcomes for patients diagnosed during adolescence
and young adulthood with the most common bone sarcomas,
osteosarcoma (OS), and Ewing sarcoma have improved over
the past 30 years with the evidence-based introduction of
intensive chemotherapy, wide-margin surgery, and, for some,
radiation treatment [1-5]. The 5-year survival rate has improved
especially for patients aged younger than 25 years [6]. Bone
sarcomas and their treatments have a direct impact on organ
function, activities of daily life, mobility, and quality of life
(QoL), including emotional and physical well-being [5,7,8].
The impact on QoL is a further concern as the majority of
patients are diagnosed during adolescence and young adulthood,
a crucial time for achieving developmental milestones. As
expected, children, adolescents, and young adults diagnosed
with bone sarcomas generally report lower levels of
health-related quality of life (HRQoL) after surgery compared
with the general population, within the domains of physical
functioning and overall well-being [8-10]. In addition to physical
functioning, patients receiving treatment for a high-grade bone
sarcoma also show significantly poorer social functioning [8,10].
This includes lower levels of autonomy and independence when
compared with matched healthy peers [8]. The intensive
treatment regime as for high-grade bone sarcoma can also
compromise QoL [11]. To date, the majority of studies have
lacked large sample sizes and standardized treatment and have
utilized varying QoL measures [12]. Furthermore, most former
studies reported QoL only after surgery; only a few studies
conducted prospective assessments from diagnosis to completion
of therapy [13], and no study so far has been reported in the
setting of a randomized trial.
Describing the impact of therapy on QoL from the patients’
perspective will lead to a better understanding of the short- and
long-term treatment-related side effects and how they can best
be managed to improve patient-centered care [12]. In addition,
improving QoL during and after bone sarcoma treatment is
thought to improve satisfaction and compliance with care and
clinician-patient/family communication, which subsequently
improves treatment decision [14,15]. Furthermore, through early
QoL assessment, undiagnosed psychosocial and physical
morbidities can be assessed [15] and potential interventions can
be implemented early during treatment. The objective of this
study was to assess QoL during and after OS therapy in the
context of the EURopean AMerican Osteosarcoma Study-1
(EURAMOS-1). In this paper, we describe the prospective
design of the EURAMOS-1 QoL assessment at 4 timepoints,
the initial characteristics and participation rates of the study
cohort at registration. In addition, we have explained the QoL
substudy processes in detail.
Methods
Brief Characteristics and Inclusion Criteria of the
European American Osteosarcoma Study-1 Trial
EURAMOS-1 contained 2 randomizations (4 treatment arms)
to test treatment strategies for resectable high-grade skeletal OS
based on histological response to preoperative chemotherapy
(ISRCTN 67613327). The full details are presented elsewhere
[16-19]; for an overview on the trial design, see Figure 1. The
study recruited patients between 2005 and 2011. Overall, 17
countries from 4 study groups participated in the trial. The
participating study groups were the Children’s Oncology Group
(COG), the Cooperative Osteosarcoma Study (COSS) group,
the European Osteosarcoma Intergroup (EOI), and the
Scandinavian Sarcoma Group (SSG). All participating countries
are listed by study group in Multimedia Appendix 1. QoL was
assessed prospectively as a secondary outcome measure in all
4 treatment arms across 4 timepoints during and after treatment.
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Figure 1. Timepoints for QoL assessment during treatment in EURopean AMerican Osteosarcoma Study-1 (EURAMOS-1). E1: first assessment
timepoint; E2: second assessment timepoint; E3: third assessment timepoint; E4: fourth assessment timepoint; QoL: quality of life.
Inclusion Criteria for Quality-of-Life Assessment
Within European American Osteosarcoma Study-1
Patients were eligible for inclusion if the following criteria were
fulfilled: diagnosis of previously untreated resectable high-grade
OS (any site except craniofacial sites) and they were diagnosed
between the ages of 5 years and 40 years.
Questionnaires
No single questionnaire was appropriate for use in all countries
for all ages at the time of trial planning. Therefore, the
investigators compromised on the use of 1 questionnaire for
adults (≥16 years; European Organization for Research and
Treatment of Cancer—Quality of Life-Core Questionnaire C30
[EORTC-QLQ-C30]) [20] and 2 age-adapted questionnaires
for pediatric patients (self-report and parallelized proxy report):
Pediatric Quality of Life Questionnaire (PEDQoL) [21,22] in
Central Europe and Scandinavia and Pediatric Quality of Life
Inventory (PedsQL) [23,24] in North America and EOI-related
countries (eg, United Kingdom or Belgium). QoL assessment
was not possible in Hungary, Finland, and the Czech Republic
because of a lack of validated translations of the QoL measures
as of the time of study development. Wherever possible, the
patient completed his/her own questionnaire and a parent filled
in a (additional) proxy questionnaire until the patient turned 18
years.
European Organization for Research and Treatment of
Cancer—Quality of Life-Core Questionnaire C30
The EORTC-QLQ-C30 is a patient-reported questionnaire that
has 8 domains assessing particular aspects significant to adult
patients with cancer: 5 functional domains (Physical=PF,
Role=RF, Cognitive=CF, Emotional=EF, and Social
Function=SF) and 3 symptom scales (Fatigue=FA, Pain=PA,
and Nausea and Vomiting=NV). In addition to these scales,
there is a global QoL scale and several single items assessing
often-reported symptoms (dyspnoe, insomnia, appetite loss,
constipation, diarrhea, and financial difficulties). Psychometric
properties of the EORTC-QLQ-C30 are proven; the
questionnaire is validated cross-culturally in different languages
and used in prospective clinical trials in adult patients [25,26].
The EORTC-CLC-Q30 data were divided into 2 age groups
(16-17 years and ≥18 years). This allowed us to compare a group
that mostly will be treated within a pediatric setting and a group
of adult participants.
Pediatric Quality of Life Inventory
The PedsQL is a modular questionnaire instrument designed to
measure HRQoL in children and adolescents aged between 2
and 18 years. The 23-item PedsQL 4.0 Generic Core Scale
implemented in this study assesses the domains physical
functioning (8 items), Emotional Functioning (5 items), Social
Functioning (5 items), and School Functioning (5 items). In
addition, a Psychosocial Health Summary Score can be derived
from the questionnaire [23]. A 5-point response scale is utilized
across child self-reports for ages 8 to 18 years and parent proxy
reports (0=never a problem to 4=almost always a problem).
The aggregated reference data of international cohorts (eg, the
United States and Great Britain) are available according to the
age groups expected in this study [23,27,28].
Pediatric Quality of Life Questionnaire
This cancer-specific questionnaire was developed to assess QoL
in children [21,22]. It contains 48 items in which 6 domains can
be identified: Physical Functioning and Pain (9 questions),
Emotional Functioning (6 questions), Body Image (9 questions),
Social Functioning—Friends and Family (12 questions),
Cognition (6 questions), and Autonomy (6 questions), as well
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as 2 questions about general well-being. Reference data (raw
data as well as aggregated data) from unselected German healthy
controls are provided according to the age groups expected in
this study [22].
Assessment Timepoints
QoL was measured prospectively at 4 timepoints reflecting
important therapy milestones. The initial assessment at timepoint
1 (E1) was planned at week 5 after the start of preoperative
chemotherapy (±1 week) but before surgical resection. E1 was
debated considerably as investigators were interested in
pretreatment QoL assessments, but it was recognized that it is
difficult to obtain these data before initiation of treatment, and
this would result in missing QoL forms for that timepoint.
Timepoint 2 (E2) was planned 10 weeks after definitive surgery
for a primary tumor (± 2 weeks) as a short-term assessment
following surgery. Timepoints 3 (E3) and 4 (E4) were planned
18 and 36 months after the start of therapy (± 1 month),
respectively, and were in place to assess long-term outcomes
following therapy. An additional timepoint between E2 and E3
was considered, but it was felt to be too burdensome. This
prospective assessment across the different treatment arms
allows for cross-sectional comparisons (Figure 1) and for
changes across time. To include as much information as
possible, a few delayed questionnaires were also taken into
account for analysis if the questionnaire was received in a
comparable treatment period (eg, if timepoint E1 was completed
before surgery).
Design, Organization, and Study Structure
The 4 study groups (COG, COSS, EOI, and SSG) established
an infrastructure to ensure successful implementation of the
EURAMOS-1 trial [19]. Ethical approval for the QoL substudy
was obtained in 2005 from the ethical authority of the University
Düsseldorf and subsequently in all of the participating study
groups. Common data elements were agreed to standardize data
collection [19]. The Quality of Life Coordinating Center
(QLCC) in Germany was responsible for the QoL data storage
and management. German patients returned questionnaires
directly to QLCC. For other patients, the institutions sent the
completed questionnaires to the national study groups, which
transferred them to QLCC by post (SSG and EOI) or
electronically (COG; Figure 2).
Figure 2. Logistics of health-related quality of life (HRQoL) assessment during EURopean AMerican Osteosarcoma Study-1 (EURAMOS-1). COG:
Children’s Oncology Group; COSS: Cooperative Osteosarcoma Study; EOI: European Osteosarcoma Intergroup; QLCC: Quality of Life Coordinating
Center; QoL: Quality of Life; SSG: Scandinavian Sarcoma Group.
Table 1 shows the questionnaires by age and source of report.
Patients’ and parents’ data were assessed independently and in
parallel. QLCC was responsible for data entry, quality control,
data base maintenance, and periodic reporting of the status of
the QoL substudy. A comprehensive system of error checking
was used to detect out-of-range or inconsistent values. If
available, errors were compared with any paper records to
determine the correct data values if discrepancies were found.
The study was open from 2005 to 2011.
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Table 1. Quality-of-life questionnaires according to age range and source of report.
Quality-of-life questionnairesAge range and source of report
European Organization for




Pediatric Quality of Life Inventory (Varni et al
[24])
Pediatric Quality of Life Ques-







Descriptive analyses were performed for baseline patients’
characteristics as well as for the proxy reports. Categorical
variables are reported as absolute and relative frequencies.
Continuous variables are shown as mean, SD (±), median and
range (minimum-maximum). Inferential statistical analyses
were performed using Fisher exact tests for categorical variables
and nonparametric methods (ie, Mann-Whitney U tests and
Kruskal-Wallis tests) for continuous variables.
The comparison between QoL substudy participants and
nonparticipants included a multivariable analysis using a logistic
regression for modeling the probability for being a QoL
Participant. The following variables were included in the full
model: study (COG [reference category], COSS, EOI, and SSG),
age (in years), gender (female vs male [reference category]),
lung metastases (no and yes [reference category]), other
(nonlung) metastases (no and yes [reference category]), and
pathological fracture (no and yes [reference category]). COSS,
EOI, and SSG also allowed participants to be defined as having
possible metastases (in addition to yes and no), COG did not
do so; therefore, all possible metastases were classified as no
metastases.
In addition, the logistic regression was calculated for each study
group separately. Odds ratios with 95% CI and Wald test P
values were reported from the full model. Statistical analyses
were performed using SAS software, version 9.4 for Windows
(SAS Institute). All P values and CIs are exploratory without
adjustment for multiplicity.
Results
Study Participants at Timepoint E1
The EURAMOS-1 protocol registered 2260 patients who were
recruited between April 2005 and June 2011. Among them,
97.92% (2213/2260) were eligible for QoL assessment and
could participate in terms of questionnaire availability. For
61.86% (1369/2213) of patients, a QoL evaluation at timepoint
E1 before surgery (Figure 3) was available. Nearly one-third
(36.38%) of the QoL substudy participants at E1 were aged
older than 16 years at timepoint E1 (n=498/1369) and 803/1369
(58.66%) were male. For the pediatric QoL substudy participants
aged younger than 16 years (n=871), a completed pediatric
self-assessment was available for 852 participants and a
completed pediatric parent-proxy assessment was available for
836 participants (for an overview, see Figure 3). In addition,
135 patients older than 16 years filled in a pediatric
questionnaire, and so finally, 987 participants with an available
pediatric self-assessed questionnaire remained. Of the 987
patients with an available pediatric questionnaire at E1, 302
filled in the PEDQoL version and 685 filled in the PedsQL
version (Table 2).
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Figure 3. Flowchart regarding quality of life (QoL) eligibility and participation at timepoint E1, split by age and self versus proxy assessment.
EORTC-QLQ-C30: European Organization for Research and Treatment of Cancer—Quality of Life-Core Questionnaire C30; PEDQOL: Pediatric
Quality of Life; PedsQL: The Pediatric Quality of Life Inventory; E1: first assessment timepoint.
A similar proportion can be found for the parent-proxy
assessment. In addition, 423 patients completed the
questionnaire for adults (EORTC-QLQ-C30; Table 2).
As patients between 16 and 18 years of age were asked to
complete both a pediatric self-assessment and an adult
questionnaire according to the compilation of questionnaires
agreed before the start of the study, 2 different self-assessment
questionnaires are evaluable for one participant. Subsequently,
the numbers of questionnaires are higher than the number of
participants on the lower part of Figure 3.
Tables 2 and 3 give an overview of patient characteristics,
grouped by the availability of self- and proxy reports at
timepoint E1. For some patients, a proxy and a self-report are
available, for others, only a proxy or a self-report is available;
therefore, the numbers on proxy questionnaires are reported
separately.
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Table 2. Number and characteristics of quality-of-life substudy participants (self-reported) at timepoint 1 (E1) by questionnaire.
Quality-of-life questionnairesCharacteristics
Adult questionnaire (n=423)Pediatric questionnaires (n=987)
European Organization for Re-
search and Treatment of Can-
cer—Quality of Life-Core
Questionnaire C30
Pediatric Quality of Life Inven-
tory (n=685)
Pediatric Quality of Life Ques-
tionnaire (n=302)
292 (69.0)395 (57.7)152 (50.3)Sex (male), n (%)
Age (years)
—a610 (89.1)242 (80.1)≥5-<16, n (%)
—b75 (10.9)60 (19.9)≥16, n (%)
210 (49.7)—b—b16-17
213 (50.4)—a—a≥18
20.3 (5.2)12.8 (2.9)13.4 (2.9)Overall mean (SD)
Study groups, n (%)
216 (51.0)578 (84.4)0 (0.0)Children’s Oncology Group
90 (21.3)0 (0.0)182 (60.3)Cooperative Osteosarcoma Study Group
90 (21.3)107 (15.6)56 (18.5)European Osteosarcoma Intergroup
27 (6.4)0 (0.0)64 (21.2)Scandinavian Sarcoma Group
Location site, n (%)
4 (1.0)3 (0.4)0 (0.0)Missing
65 (15.4)95 (13.9)30 (9.9)Upper extremity
344 (81.3)584 (85.3)270 (89.4)Lower extremity
10 (2.4)3 (0.4)2 (0.7)Other
Lung metastases, n (%)
3 (0.7)3 (0.4)0 (0.0)Missing
43 (10.2)99 (14.5)32 (10.6)Yes
377 (89.1)583 (85.1)270 (89.4)Noc
Other (nonlung) metastases, n (%)
3 (0.7)3 (0.4)0 (0)Missing
8 (1.9)18 (2.6)12 (4.0)Yes
412 (97.4)664 (96.9)290 (96.0)Noc
Pathological fracture at diagnosis, n (%)
3 (0.7)4 (0.6)0 (0)Missing
375 (88.7)589 (86.0)283 (93.7)No
45 (10.6)92 (14.4)19 (6.3)Yes
aQuestionnaire not intended for this age group.
bInformation of this age-category is reported elsewhere in the same table.
cPossible metastases were combined with no metastases.
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Table 3. Number and characteristics of quality-of-life substudy participants (proxy report) at registration by questionnaire.
Quality-of-life questionnairesCharacteristics
Pediatric Quality of Life Inventory (n=660)Pediatric Quality of Life Questionnaire (n=295)
388 (58.8)147 (49.8)Sex (male), n (%)
Age (years)
598 (90.6)238 (80.7)≥5-<16, n (%)
62 (9.4)57 (19.3)≥16, n (%)
12.2 (2.9)13.0 (2.8)Overall mean (SD)
Study groups, n (%)
548 (83.0)N/AaChildren’s Oncology Group
N/A180 (61.0)Cooperative Osteosarcoma Study group
112 (17.0)55 (18.6)European Osteosarcoma Intergroup
0 (0.0)60 (20.3)Scandinavian Sarcoma Group
aN/A: not applicable.
Participation by Timepoint
Table 4 shows how many patients provided the HRQoL
self-report questionnaire, broken down by completed timepoint
and all of their combinations during the study. As there were
1369 participants at E1 (Figure 3) and overall there were 1338
patients for timepoint E1, there were 31 participants at timepoint
E1 with a proxy report only. The table shows a decreasing linear
trend of participation with trial progress, starting with
n=1338/2213 (60.46%) self-reports at timepoint 1 and
continuing with n=934/2213 (42.21%) at timepoint E2 and
n=668/2213(30.19%) and n=450/2213 (20.33%) at timepoints
3 and 4, respectively. However, the largest decline is between
timepoint E1 and E2, and accordingly, the highest number of
participants with n=454/2213 (20.52%) provided an
self-assessment questionnaire at E1 but did not complete a
questionnaire at any further timepoint, followed by those group
of participants who provided self-assessment questionnaires at
all 4 timepoints (273/2213; 12.34%).
Table 5 indicates for how many patients HRQoL proxy
assessments were provided, again broken down by each
timepoint and all of their combinations. With regard to Table
5, it is important to note that a proxy report was mandatory for
child and adolescent patients, including those aged 17 years.
Given this subgroup of 1778 patients, n=950/1778 (53.4%) of
all parents of these patients provided a proxy report at timepoint
E1.
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Table 4. Number of patients with available self-assessment at any possible combination of timepoints during study (N=2213).
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Table 5. Number of patients with an available proxy assessment at any possible combination of timepoints during the study (N=2213).






















Quality of Life—Nonparticipant Analyses at Timepoint
E1
The nonparticipant analyses were performed on patient level if
any age-appropriate questionnaire (self- or proxy report or
pediatric or adult questionnaire) was available at timepoint E1.
Demographic and disease-related characteristics for QoL
substudy participants and nonparticipants at timepoint E1 of
the QoL study are listed in Table 6. No statistically significant
differences in the participation rates with respect to age or
gender were seen. Participation rates differed substantially
between national study groups (67% COG, 80% SSG, 56%
EOI, and 50% COSS). Patients from the COSS group and EOI
were less likely to participate in the QoL study’s baseline
assessment (OR 0.48, 95% CI 0.386-0.600 and OR 0.61, 95%
CI 0.482-0.759, respectively) compared with patients from
COG, whereas patients from the SSG had a higher participation
rate than those from COG (OR 1.97, 95% CI 1.223-3.172).
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Table 6. Comparison of quality of life (QoL) nonparticipants and QoL participants at timepoint 1 (E1) in the overall cohort (N=2213).
QoL overall sample at registrationCharacteristics
QoL participants (n=1369)QoL nonparticipants (n=844)
803 (58.66)498 (59.00)Sex (male), n (%)
Age (years)
871 (63.62)523 (61.97)≥5-<16, n (%) 
498 (35.94)321 (38.03)≥16, n (%) 
15.0 (5.10)15.4 (5.6)Overall mean (SD) 
  Study groups, n (%)
784 (57.27)380 (45.02)Children’s Oncology Group 
241 (17.60)242 (28.67)Cooperative Osteosarcoma Study group 
252 (18.41)199 (23.58)European Osteosarcoma Intergroup 
92 (6.72)23 (2.73)Scandinavian Sarcoma Group 
Tumor location, n (%)
7 (0.51)9 (1.07)Missing 
188 (13.73)130 (15.40)Upper extremity 
1159 (84.66)700 (82.94)Lower extremity 
15 (1.10)5 (0.59)Other 












aPossible metastases were combined with no metastases.
There was no evidence that age (P=.27) or gender (P=.61)
influenced participation. Individual models for each study group
revealed that within the COG group, female patients were less
likely to participate (OR 0.76, 95% CI 0.585-0.974; P=.03),
whereas female patients were more likely to participate within
the COSS group (OR 1.57, 95% CI 1.070-2.29; P=.02). For the
EOI and the SSG, gender did not have an influence on the
participation.
Considering participation rates at timepoint E1 with regard to
disease characteristics, no differences in participation were
obtained with regard to major tumor site (P=.29), occurrence
of pathological fracture at diagnosis (P=.13), and initial
presentation with metastasis (lung; P=.10), or other sites (P=.13)
before registration. Patients with femur as the primary site
contributed most frequently to the baseline QoL assessments
(695; 51.0%), whereas patients with radius as the primary site
participated relatively less frequently (16; 1.2%).
Discussion
Principal Findings
Here, we describe the QoL substudy embedded in the
international OS trial, EURAMOS-1. A total of 4 national study
groups that included 17 countries contributed to the study and
resulted in the first prospective QoL international study of OS.
We collected at least at timepoint E1 QoL information from
nearly 1400 patients with an age range from 5 to 40 years. Most
reported OS QoL studies were smaller and/or have focused only
on posttreatment or were not prospective from the time of
diagnosis [8-10]. This prospective study aimed to provide
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information not previously reported in the literature and results
will help to develop interventions to improve QoL.
Overall, in EURAMOS-1, there were no differences in
participation rates at timepoint E1 with regard to the age, gender,
site of primary tumor involvement, occurrence of pathological
fracture, or occurrence of lung or other metastases at diagnosis
between QoL substudy participants and nonparticipants.
However, a difference of participation rates between the
different national study groups was evident. Logistic regression
revealed that patients from the COG were more likely to
participate in the QoL assessment compared with COSS and
EOI patients, but they were less likely to participate compared
with patients from the SSG. In addition, within national study
groups (COSS and COG), some significant differences in gender
participation were seen. Beside differences in the national study
group structure, cultural tendencies could have influenced the
different response rates. Further investigation into these
differences is warranted.
Comparison With Previous Work
Although there was a participation rate of about 60% at
timepoint E1 and the participation rates regarding
self-assessment decreased to just over 20% at timepoint E4, this
is reasonable given the characteristics of the study cohort (eg,
in terms of participant’s age range and the number of countries
involved). In other HRQoL studies involving children with
cancer, the response rates have varied between 58% and 98%
[29]. A recent multicenter prospective study including children
with lymphoblastic leukemia reported a participation rate of
63% and obtained also a less pronounced but substantial linear
decline of participation with study progress [30]. One must keep
in mind that investigating QoL in adolescents and young adults
(AYAs) may be even more difficult (in this study, 56.5% were
aged ≥13 years) because of their developmental status and
pursuit of autonomy. These circumstances probably influenced
the participation rates. In addition, declining participation rates
over the course of the trial are also influenced by overall and
event-free survival (eg, at 36 months after biopsy, they were
approximately 80% and 60%, respectively) [31]. Rosenberg’s
study [32] of only AYA patients reported a response rate of
only 74% at a single timepoint, even when patients were
rewarded for participation. There are no comparable sarcoma
trials that include QoL and cover such a broad study age range
from various countries and ethnicities. Compared with other
international QoL substudies in adult cancer RCTs, these studies
obtained higher participation rates at baseline in different
diagnoses, for example, leukemia [33] or ovarian cancer [34,35].
However, these trials differed also in terms of assessment
method. For instance, provision of an electronic device may
have increased the likelihood of participating in the study by
Topp et al [33]. Moreover, only adult but no adolescent patients
were included. In the future, this could be improved by
incorporating Web-based or mobile apps, according to the
recommendation by Johnston et al [29] who explored reasons
for nonparticipation in QoL studies on children with cancer and
their parents. They came to the conclusion that this may address
many logistical challenges.
Limitations
Some limitations have to be addressed. We did not assess the
level of baseline pain or the extent of anxiety regarding the
diagnosis or the urgency to start treatment; both variables may
have an important influence on participation rate. Large sample
sizes increase the chance of obtaining significant results.
Therefore, our results have to be interpreted cautiously. The
unavailability of a common QoL questionnaire usable across
all groups/countries is a limitation in comparison across groups
but was unavoidable. Given the large number of participating
sites, how the questionnaires were provided to families and
administered may lead to differences. This prospective design
does allow analysis of changes over time and at an
intraindividual level; however, the representativeness of the
collected data may be affected by low participation rates
(particularly in respect to the reduced sample size at timepoint
E4). In addition, the comparability of measurements is limited
as the questionnaires changed (at the age of 16 years) between
timepoints and differed between national study groups;
participants could also choose to participate only at certain
timepoints. To overcome this obstacle, we plan on using a
linking method for score conversion [36] for the subscales with
sufficient conceptual overlap between questionnaires. We will
base the linking of scores on a subset of participants who
completed 2 questionnaires at the same timepoint (single-group
design) according to schedule. We will assess concordance
using appropriate measures (eg, Bland-Altman plots and Lin
correlation concordance coefficient) [37,38].
Conclusions
Despite some of the limitations, this is largest prospective
assessment of QoL in OS therapy. Further analyses will be able
to look at prospective changes and be able to look at long-term
outcomes and differences between different demographic
groups. This study also highlights the ability of clinicians and
researchers to work together to perform large QoL investigations
across different national study groups. For such an endeavor to
succeed, there needed to support from each national study group
that includes first recognizing the importance of QoL
assessments, the provision of infrastructure for the collection
and management of QoL data, the identification of lead QoL
investigators for each group, and time/support for meeting as a
group. Through the initial phases of the development of this
study, we needed to come together to identify the most
appropriate QoL questionnaires that were available at the time
that it was validated for the different involved
countries/languages, had similar domains, and can span the age
range of participants. We then had to determine how often and
when assessments will be done while accounting for structural
differences in the various groups/countries in how they delivered
therapy and administered questionnaires and ensuring that
questionnaires were not too burdensome. After intensive
discussions, compromises were made regarding the timing of
initial QoL assessment and the number of assessments. In terms
of administration, it was decided that the administration and
tracking of the assessments has to be in the hands of the national
study groups and that centralized administration would not be
possible. However, the data management and quality control
checks were centralized with the QLCC taking the lead. Each
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national study group determined its own system of transferring
the QoL forms/data to the QLCC. Overall, this was a successful
endeavor, and we hope learnings from this partnership will lead
to future studies. With this study, future analyses will lead to a
better understanding of the impact OS therapy has on QoL and
how patient and particular disease characteristics influence QoL
in the short and long term and how QoL changes over time.
This will help to ameliorate or prevent the potential decline in
psychosocial and physical morbidities of patients undergoing
OS treatment.
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